Neurogene price target raised to $72 from $54 at Baird

Baird analyst Joel Beatty raised the firm’s price target on Neurogene (NGNE) to $72 from $54 and keeps an Outperform rating on the shares. The firm said they are positive on the shares after the company announced initial interim clinical data for gene therapy NGN-401 in Rett syndrome. Baird believes the efficacy data is more likely than not good enough to support approval.